ChyloCure’s Chylobinoid® product is designed to predictably deliver CBDa (the most abundant and potent of all cannabinoids) and other non-psychoactive cannabinoids such as CBD by way of stable and highly absorbable complexes that can be formulated into easy to consume products (topical creams, oral capsules, gummies, etc.). Additionally, Chylobinoid products are green, solvent free, and free of mycotoxins, pesticides, heavy metals and THC.
Long COVID/PASC (Post-acute sequelae of COVID-19) can occur in around 30% of patients and is characterized by a wide variety of symptoms (fatigue, post-exertional malaise, palpitations, headaches, memory issues, etc.) that can persist four weeks or longer after the initial infection. The continued cyclical surge of new COVID-19 variants and infected individuals will likely increase the number of Long COVID/PASC cases in the future. The continued development and testing of innovative approaches to treat acute COVID-19 infections, along with the unpredictable consequences Long COVID/PASC, is therefore necessary and desirable.
Cannabinoids (CBDa, CBGa and CBD) are known to reduce inflammation, oxidative (metabolic) stress and immunologic stimulation, and can consequently interrupt the relentless cycle of microembolic (blood clot) formation, systemic inflammation, vascular injury and progressive tissue damage which characterizes this disorder. Many preliminary in vitro and ex vivo studies, along with early clinical observational investigations, have strongly pointed to the potential use of cannabinoid products for acute and Long COVID/PASC disease management. In fact, given the positive, but limited experience we’ve had in treating several patients with PASC-related symptoms, ChyloCure’s Chylobinoid® products may provide a very effective, safe, and convenient approach to address this pressing need.
